To verified the tumour-specific cytotoxic T lymphocyte (CTL) response of treatment, the spleen lymphocytes isolated from different treatment groups (control, anti-SIRPα, OH2, and OH2+ anti-SIRPα) were co-cultured with CT26 cells in vitro at target cell/effector cell (T:E) ratios of 1:100, 1:50, and 1:25. This evidence concerns the gene SIRPA and neoplasm.